A clinical study (NCT00938626) targeting myeloma precursor cells in standard and high-risk MM patients administered the patients with anti-CD3 × anti-CD2 BsAb-armed activated T cell infusions prior to autoSCT (230). The gene discussed is CD2; the disease is Miyoshi myopathy.